Clicky

Sumitomo Dainippon Pharma CO Ltd(SMDPY)

Description: Sumitomo Pharma Co., Ltd. engages in the manufacture and sale of pharmaceuticals, food ingredients and additives, veterinary medicines, and others in Japan, North America, China, and internationally. The company offers pharmaceutical products, such as therapeutic agents for Parkinson's disease, uterine fibroids, depression, type 2 diabetes, systemic fungal infection, hypertension, pruritus, advanced prostate cancer, overactive bladder, chronic obstructive pulmonary disease, angina pectoris, and arrhythmia. It also provides products for atypical antipsychotic, cultured thymus tissue for pediatric congenital athymia, antiepileptic, and carbapenem antibiotic; and Fabry disease drugs. In addition, the company offers food ingredients and additives, such as polysaccharides, as well as seasonings, such as soups or bouillons; and chemical product materials, which include pharmaceutical excipients, personal care products, coatings and industrial materials, and electronic materials. Further, it provides veterinary medicines for companion animals, such as dogs and cats; and livestock comprising cattle, swine, poultry, horses, and aquacultured fish. Sumitomo Pharma Co., Ltd. has partnerships with Healios K.K.; Keio University; RIKEN; the Center for iPS Cell Research and Application; Kyoto University; and Aikomi Co., Ltd., as well as a joint development agreement with SanBio Company Limited; and collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. The company also has a strategic alliance with Roivant Sciences Ltd. The company was formerly known as Sumitomo Dainippon Pharma Co., Ltd. and changed its name to Sumitomo Pharma Co., Ltd. in April 2022. The company was incorporated in 1897 and is headquartered in Osaka, Japan. Sumitomo Pharma Co., Ltd. is a subsidiary of Sumitomo Chemical Company, Limited.


Keywords: Pharmaceutical Pharmaceutical Products Diabetes Personal Care Products Prostate Cancer Parkinson's Disease Hypertension Food Ingredients Depression Economy Of Japan Sumitomo Group Chronic Obstructive Pulmonary Disease Arrhythmia Overactive Bladder Uterine Fibroid Fabry Disease Pruritus Angina Pectoris Pharmaceutical Excipients Kyoto University Sumitomo Chemical Sumitomo Dainippon Pharma Center For I Ps Cell Research And Application Chemical Product Materials Keio University Sunovion Systemic Fungal Infection

Home Page: www.sumitomo-pharma.com

6-8, Doshomachi 2-chome
Osaka, 541-0045
Japan
Phone: 81 6 6203 5321


Officers

Name Title
Mr. Hiroshi Nomura CEO, Pres & Representative Director
Hisayoshi Kashima Sr. Director & Corp. Controller
Mr. Naoki Noguchi Exec. Officer of Corp. Governance, Corp. Communications & Sr. Director of Corp. Governance
Mr. Takuya Taguchi Sr. Exec. Officer & Exe. Director - Sales & Mktg Div. and Deputy Head of Japan Bus. Unit
Ms. Atsuko Higuchi Sr.. Exec. Officer of External Affairs, Corp. Secretariat & HR
Mr. Yoshiharu Ikeda Ph.D. Sr. Exe. Officer of Cancer, Modality & Drug Research Div., Head of Japan Busi Unit and Director
Mr. Hiroyuki Baba Sr. Exe Off. of Global Data Design, Legal Affairs. IP, IT Mgt, & Frontier Bus. Off. and Director
Mr. Toru Kimura Ph.D. EVP of Global Corp. Strategy, Regenerative & Cellular Medicine Off. and Representative Director
Dr. Shigeyuki Nishinaka Ph.D. Sr. Exe. Officer of Global Bus. Dev. & International Bus. Management and Director
Mr. Hideyuki Harada Sr. Exec. Officer of Tech. Research & Dev. Div., Mfg. Div., Deputy Head of Japan Bus. Unit

Exchange: PINK

Country: US

Currency: US Dollar ($)

Forward PE: 21.1864
Trailing PE: 31.9583
Price-to-Book MRQ: 0.6823
Price-to-Sales TTM: 0.0055
IPO Date:
Fiscal Year End: March
Full Time Employees: 6987
Back to stocks